Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,338 result(s) found. Displaying page 1,178 of 2,217.
    EudraCT Number: 2007-002476-33 Sponsor Protocol Number: NN5401-1791 Start Date*: 2007-11-30
    Sponsor Name:Novo Nordisk A/S
    Full Title: Ensayo clínico abierto y aleatorizado con tres grupos paralelos  con ajuste de dosis y 16 semanas de tratamiento para comparar la administración una vez al día de insulina SIAC 30(B), SIAC 45(B) e ...
    Medical condition: Diabetes Mellitus Tipo 2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005256-16 Sponsor Protocol Number: CSPP100A2404 Start Date*: 2008-03-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 54 week, randomized, double-blind, parallel-group, multicenter study evaluating the long-term gastrointestinal (GI) safety and tolerability of aliskiren (300 mg) compared to ramipril (10 mg) in p...
    Medical condition: Essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-006280-78 Sponsor Protocol Number: PYLHp07-01 Start Date*: 2008-03-28
    Sponsor Name:Axcan Pharma Inc.
    Full Title: Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given x 10 days With Omeprazole in Eradication of Helicobacter pylori: A Comparison to Omep...
    Medical condition: Helicobacter pylori infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019377 Helicobacter pylori infection LLT
    9.1 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) IE (Completed) DE (Completed) NL (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-002422-29 Sponsor Protocol Number: 1235.8 Start Date*: 2007-10-19
    Sponsor Name:Boehringer Ingelheim Ltd.
    Full Title: An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ...
    Medical condition: essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-004241-15 Sponsor Protocol Number: IM101-158 Start Date*: 2007-12-21
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase IIB, Multi-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis. A...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) NL (Completed) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: Removed from public view
    EudraCT Number: 2007-004729-16 Sponsor Protocol Number: 1263-301 Start Date*: 2008-01-25
    Sponsor Name:ViroPharma Incorporated
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR VERSUS ORAL GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECE...
    Medical condition: Main purpose is to assess the efficacy and safety of prophylactic use of oral Maribavir versus oral Ganciclovir to prevent cytomegalovirus disease in recipients of orthotopic liver transplants at h...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009701 CMV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) AT (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003312-65 Sponsor Protocol Number: CL2-90098-005 Start Date*: 2008-01-25
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, interna...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057840 Major depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) FI (Completed) CZ (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006150-25 Sponsor Protocol Number: 3206K1-2203-WW Start Date*: 2008-06-24
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Sta...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed) BE (Completed) AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-002062-62 Sponsor Protocol Number: ALS-TAL-201 Start Date*: 2008-10-14
    Sponsor Name:Teva Pharmaceutical Industries, Ltd
    Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral S...
    Medical condition: Amyotrophic lateral sclerosis (ALS).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052653 Amyotrophic lateral sclerosis gene carrier PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) ES (Completed) IT (Completed) BE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001566-90 Sponsor Protocol Number: A6301086 Start Date*: 2008-06-19
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent
    Full Title: A 6 MONTH, PROSPECTIVE, OPEN-LABEL MULTIPLE CENTER EXTENSION TRIAL TO EVALUATE THE LONG TERM SAFETY AND SUSTAINED EFFICACY OF FRAGMIN IN THE TREATMENT OF CHRONIC FOOT ULCERS IN DIABETIC PATIENTS WI...
    Medical condition: Diabetic Foot Ulcer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Completed) ES (Completed) NL (Prematurely Ended) CZ (Completed) FR (Completed) AT (Completed) DK (Prematurely Ended) FI (Prematurely Ended) BE (Completed) LT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002043-16 Sponsor Protocol Number: GS-EU-164-0206 Start Date*: 2008-09-02
    Sponsor Name:Gilead Sciences Europe Ltd.
    Full Title: Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi...
    Medical condition: Sujetos adultos, infectados con el VIH-1, que están siendo tratados con un régimen TARGA estable de Kivexa + Kaletra, con colesterol elevado. Adult HIV-1 infected subjects on a stable HAART regime...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005570-32 Sponsor Protocol Number: E3810-G000-301 Start Date*: 2008-08-01
    Sponsor Name:Eisai Limited [...]
    1. Eisai Limited
    2. Eisai Medical Research Inc
    Full Title: A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Dis...
    Medical condition: Erosive gastro-oesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017885 Gastrooesophageal reflux disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) HU (Completed) FR (Completed) EE (Completed) LT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-005687-27 Sponsor Protocol Number: TAK-242_301 Start Date*: 2008-08-06
    Sponsor Name:Takeda Global Research & Development Centre (Europe), Ltd. [...]
    1. Takeda Global Research & Development Centre (Europe), Ltd.
    2. Takeda Global Research & Development Centre (Europe), Ltd.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of TAK-242 Versus Placebo in Subjects With Sepsis Induced Cardiovascular and Respiratory Failure
    Medical condition: Septic shock and respiratory failure.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040070 Septic shock PT
    9.1 10038695 Respiratory failure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FI (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) FR (Completed) AT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-003148-51 Sponsor Protocol Number: F13CD-1725 Start Date*: 2008-08-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII ...
    Medical condition: Congenital Factor XIII Deficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010432 Congenital deficiency of other clotting factors LLT
    9.1 10061992 Haemophilia LLT
    9.1 10009735 Coagulation disorders congenital HLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed) AT (Completed) ES (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000952-28 Sponsor Protocol Number: 26866138-MMY-3021 Start Date*: 2008-12-17
    Sponsor Name:Janssen-Cilag International NV (JCI)
    Full Title: An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple Myeloma
    Medical condition: The subject population comprises adult male and female subjects with multiple myeloma that has relapsed or progressed after prior systemic antineoplastic therapy, presence of measurable secretory d...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003190-41 Sponsor Protocol Number: NETU-08-03 Start Date*: 2008-10-30
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Prospective Study to Assess the Efficacy, Safety and Tolerability of Three Oral Doses of Netupitant Given Once a Day (5...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-002696-27 Sponsor Protocol Number: HX575-304 Start Date*: 2008-12-04
    Sponsor Name:Hexal AG
    Full Title: An open label, single-arm, baseline-controlled, multicenter study to evaluate the efficacy, safety and immunogenicity of subcutaneous HX575 administered once a week (qw) and once every two weeks (q...
    Medical condition: Anemia associated with chronic kidney disease in pre-dialysis and dialysis subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009120 Chronic renal failure anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) SK (Prematurely Ended) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000977-39 Sponsor Protocol Number: CA163-163 Start Date*: 2008-11-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung Cancer Revised Protocol 02 incorporating Amendment 03 (vers...
    Medical condition: Advanced Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-003459-64 Sponsor Protocol Number: AFX01_202 Start Date*: 2009-03-18
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure Who Are on Hemodialysis or Do Not Require Dialysis and...
    Medical condition: Anaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058116 Nephrogenic anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001105-42 Sponsor Protocol Number: H9B-MC-BCDG Start Date*: 2008-09-16
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibit...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 08:18:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA